Nemocnice Cesky Krumlov a.s.
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The internal department at Nemocnice Cesky Krumlov a.s. is conducting studies that address anemia in patients with chronic kidney disease on dialysis. The trials compare two erythropoiesis‑stimulating agents to determine which better maintains hemoglobin levels while ensuring safety for this vulnerable population.
- Management of anemia in dialysis patients
- Optimization of hemoglobin control
- Comparative effectiveness of erythropoietin therapies
- Impact on patient quality of life
These investigations aim to refine treatment guidelines for kidney‑related blood disorders and support clinicians in delivering more precise care.
Nutritional and Metabolic Diseases
Researchers at the hospital are evaluating innovative medicines such as retatrutide and orforglipron to help individuals with obesity, overweight, and type 2 diabetes. The studies focus on reducing body weight, improving metabolic health, and lowering the risk of serious heart and kidney complications.
- Weight loss efficacy of new agents
- Cardiovascular risk reduction
- Kidney outcome improvement
- Glycemic control in diabetes
The goal is to expand therapeutic options for metabolic disorders and provide evidence that these treatments can safely improve long‑term health outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Genexine Inc.2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Genexine Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Cesky Krumlov a.s.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Efepoetin Alfa Versus Darbepoetin Alfa in Anemia Management for Chronic Kidney Disease Patients on Dialysis | Genexine Inc. | Phase III | Recruiting | Jul 2025 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Darbepoetin Alfa | 2 | Unknown | 2025-07-22 | 2025-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.